Demographics and outcomes for study population
| Patients . | Apixaban (n = 42) . | Rivaroxaban (n = 60) . | Total (N = 102) . |
|---|---|---|---|
| Age, y | |||
| Mean | 49.0 | 48.3 | 48.5 |
| SD | 10.7 | 12.4 | 11.6 |
| Sex | |||
| Female | 33 (78.6) | 51 (85.0) | 84 (82.4) |
| Male | 9 (21.4) | 9 (15) | 18 (17.6) |
| BMI, kg/m2 | |||
| Median | 36.3 | 35.5 | 35.7 |
| IQR | 28.4-41.5 | 31.5-43.7 | 30.1-43.1 |
| BMI group, kg/m2 | |||
| ≤30 | 12 (28.6) | 12 (20.0) | 24 (23.5) |
| 30-40 | 16 (38.1) | 28 (46.7) | 44 (43.1) |
| ≥40 | 12 (28.6) | 18 (30.0) | 30 (29.4) |
| Race | |||
| White | 6 (14.3) | 10 (16.7) | 16 (15.7) |
| Black | 15 (35.7) | 25 (41.7) | 40 (39.2) |
| Other/declined | 21 (50.0) | 25 (41.7) | 46 (45.1) |
| Bariatric surgery procedure | |||
| Gastric banding | 4 (9.5) | 8 (13.3) | 12 (11.8) |
| SG | 18 (42.9) | 20 (33.3) | 38 (37.3) |
| Gastric bypass | 20 (47.6) | 32 (53.3) | 52 (51.0) |
| Indication for anticoagulation | |||
| Acute VTE | 33 (78.6) | 42 (70) | 75 (73.5) |
| Chronic VTE | 9 (21.4) | 18 (30) | 27 (26.5) |
| Follow-up duration, d | |||
| Median | 137 | 240 | 187.5 |
| IQR | 61.5-375.8 | 97.8-652.0 | 82.5-627.5 |
| Recurrent VTE | 0 (0) | 1 (1.7) | 1 (1.0) |
| Major bleeding | 0 (0) | 3 (5.0) | 3 (2.9) |
| CRNMB | 1 (2.4) | 0 (0) | 1 (1.0) |
| Patients . | Apixaban (n = 42) . | Rivaroxaban (n = 60) . | Total (N = 102) . |
|---|---|---|---|
| Age, y | |||
| Mean | 49.0 | 48.3 | 48.5 |
| SD | 10.7 | 12.4 | 11.6 |
| Sex | |||
| Female | 33 (78.6) | 51 (85.0) | 84 (82.4) |
| Male | 9 (21.4) | 9 (15) | 18 (17.6) |
| BMI, kg/m2 | |||
| Median | 36.3 | 35.5 | 35.7 |
| IQR | 28.4-41.5 | 31.5-43.7 | 30.1-43.1 |
| BMI group, kg/m2 | |||
| ≤30 | 12 (28.6) | 12 (20.0) | 24 (23.5) |
| 30-40 | 16 (38.1) | 28 (46.7) | 44 (43.1) |
| ≥40 | 12 (28.6) | 18 (30.0) | 30 (29.4) |
| Race | |||
| White | 6 (14.3) | 10 (16.7) | 16 (15.7) |
| Black | 15 (35.7) | 25 (41.7) | 40 (39.2) |
| Other/declined | 21 (50.0) | 25 (41.7) | 46 (45.1) |
| Bariatric surgery procedure | |||
| Gastric banding | 4 (9.5) | 8 (13.3) | 12 (11.8) |
| SG | 18 (42.9) | 20 (33.3) | 38 (37.3) |
| Gastric bypass | 20 (47.6) | 32 (53.3) | 52 (51.0) |
| Indication for anticoagulation | |||
| Acute VTE | 33 (78.6) | 42 (70) | 75 (73.5) |
| Chronic VTE | 9 (21.4) | 18 (30) | 27 (26.5) |
| Follow-up duration, d | |||
| Median | 137 | 240 | 187.5 |
| IQR | 61.5-375.8 | 97.8-652.0 | 82.5-627.5 |
| Recurrent VTE | 0 (0) | 1 (1.7) | 1 (1.0) |
| Major bleeding | 0 (0) | 3 (5.0) | 3 (2.9) |
| CRNMB | 1 (2.4) | 0 (0) | 1 (1.0) |
Data are presented as n (%) unless otherwise indicated.
SD, standard deviation.